Selective or Nonselective Endothelin Receptor Blockade in Pulmonary Arterial Hypertension

This publication has 11 references indexed in Scilit:

• Detectable Serum Cardiac Troponin T as a Marker of Poor Prognosis Among Patients With Chronic Precapillary Pulmonary Hypertension
  Circulation, 2003
• Beraprost therapy for pulmonary arterial hypertension
  Journal of the American College of Cardiology, 2003
• Effects of the oral endothelin-receptorantagonist bosentan on echocardiographicand doppler measures in patients with pulmonary arterial hypertension
  Published by Elsevier ,2003
• Ventricular mass index using magnetic resonance imaging accurately estimates pulmonary artery pressure
  European Respiratory Journal, 2002
• Bosentan Therapy for Pulmonary Arterial Hypertension
  New England Journal of Medicine, 2002
• Continuous Subcutaneous Infusion of Treprostinil, a Prostacyclin Analogue, in Patients with Pulmonary Arterial Hypertension
  American Journal of Respiratory and Critical Care Medicine, 2002
• Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebocontrolled study
  The Lancet, 2001
• Long-Term Treatment of Primary Pulmonary Hypertension with Aerosolized Iloprost, a Prostacyclin Analogue
  New England Journal of Medicine, 2000
• Clinical Correlates and Prognostic Significance of Six-minute Walk Test in Patients with Primary Pulmonary Hypertension
  American Journal of Respiratory and Critical Care Medicine, 2000
• Serum Uric Acid Levels Correlate with the Severity and the Mortality of Primary Pulmonary Hypertension
  American Journal of Respiratory and Critical Care Medicine, 1999